about
Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's diseaseFunctional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's DiseaseEffects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's DiseaseJAKMIP1, a Novel Regulator of Neuronal Translation, Modulates Synaptic Function and Autistic-like Behaviors in Mouse.Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease.Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntington's DiseaseCYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtinMitochondria in Huntington's disease.Behavioral phenotyping of heterozygous acetylcholinesterase knockout (AChE+/-) mice showed no memory enhancement but hyposensitivity to amnesic drugs.Striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo.Hyposensitivity to the amnesic effects of scopolamine or amyloid beta(25-35) peptide in heterozygous acetylcholinesterase knockout (AChE(+/-)) mice.Capucin does not modify the toxicity of a mutant Huntingtin fragment in vivo.The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin.CREB controls cortical circuit plasticity and functional recovery after stroke.Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease
P50
Q27011417-B85B9B3C-E15E-4BE1-A226-85D202349133Q27015687-A2123D10-8FAC-4B84-8986-F303ECFF129FQ28486205-54A1FABA-7D09-4E23-A63C-B4C7070E0A3DQ28771493-707F60CB-6785-47DE-8C71-ED40D9EC060CQ35239326-E6357CE8-7AA3-48DB-891C-53872CC410FAQ35867178-840BAC9B-376F-409F-B509-40129F1931F0Q36615488-244C0532-235F-44F7-865B-EE0609C27850Q36940345-1EEF137F-B0ED-49B0-9784-AB78CD948C33Q37153804-529C3E6D-9412-404E-BF73-2EABC2F6C721Q37580111-2A85F777-E1F1-421B-93A5-E57C5DF2966FQ43274144-A388169A-3B2D-4F7D-8C0A-E05D8C5AF189Q45303836-9179D69E-ABF8-4801-8997-01C2695576CDQ46557196-8EE3CAC3-90AE-4ED7-B934-EB3C63304149Q48641662-0DC964D5-59C1-488A-92B7-B3C59D0E8143Q52357361-D94A9797-DAC4-4943-96E4-9DE6F0026827Q55039386-A6E0E452-EE06-4446-AD73-ACA804F23FE1Q93347779-540FC5B0-AD13-4918-B608-E80A17E114FD
P50
description
researcher ORCID ID = 0000-0002-7851-0102
@en
wetenschapper
@nl
name
Laurie Galvan
@ast
Laurie Galvan
@en
Laurie Galvan
@es
Laurie Galvan
@nl
type
label
Laurie Galvan
@ast
Laurie Galvan
@en
Laurie Galvan
@es
Laurie Galvan
@nl
prefLabel
Laurie Galvan
@ast
Laurie Galvan
@en
Laurie Galvan
@es
Laurie Galvan
@nl
P106
P31
P496
0000-0002-7851-0102